Prostate Cancer

E fforts to save lives by detecting cancer earlier have stalled because British patients are fearful of wasting GPs’ time, a report has found. A major review concludes that thousands of deaths could be avoided each year if the UK were to match international cancer standards, but that progress is being hampered due in part to embarrassment over troubling busy family doctors with what seem like minor symptoms. The Health Foundation report said more than a fifth of patients are worried about wasting their doctor’s time. Meanwhile nearly half put off checking out symptoms because of difficulty securing an appointment. A shortage of scanners and specialist staff to operate them are also blamed in the document, written by the NHS’s former cancer chief Professor Sir Mike Richards. Britain currently ranks 35th out of 37 comparable nations for availability of CT scanners, and 31st out of 36 for MRI scanners. Sir Mike writes that the lag behind international best practice represents a...

If you’re a smoker looking for another reason to quit, consider this: in addition to raising your risk of heart and lung disease, as well as cancers of the bladder and kidney, smoking could boost the odds that you will develop aggressive prostate cancer that metastasizes, or spreads through your body. That’s according to research published by an Austrian team in 2018. The evidence connecting tobacco use with prostate cancer (which tends to grow relatively slowly) isn’t as strong as it is for other smoking-related diseases. Researchers first detected the link only after pooling data from 51 studies that enrolled over four million men. Published in 2014 , this earlier research showed that smokers have a 24% higher risk of death from prostate cancer than nonsmokers, but it left an open question: did the men who died from these other causes also have high-grade prostate cancers that had not yet been detected? Experts suspected that since smoking kills in different ways, some of those who...

A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the U.S. Men whose prostate cancer tumors are localized typically survive many years after diagnosis, whether they have surgery, radiation therapy or no treatment at all. But for a minority of men whose cancer spreads to other parts of the body and resists hormone therapy, the prognosis is poor, with fewer than a third surviving five years after diagnosis. More than 29,000 men in the U.S. die from prostate cancer each year, according to the American Cancer Society. "We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said Michae...

Dear Dr. G, I am a 40-year-old man who is reasonably fit and healthy. Although I look after myself well, as do most men approaching their forties, I begin to hear more about the prostate, but have no idea what it is, and how to look after the prostate. In the last week of Men's Health Movember, I wish to get Dr. G to put prostate health on the spotlight. What exactly is the prostate, what does it do? How do I know whether my prostate is in a good state of health? I hear in the news that prostate cancer is on the rise, is that true? I understand that the prostate is affected by diet, can you please highlight what diet is protective and what is harmful for the prostate. I also understand sedentary lifestyle can cause prostate cancer, can you enlighten us with the reasons behind such association. Lastly, I cannot put Dr. G on the spot about the prostate and not talk about sex. Is there a link between prostate cancer and sex? Would too much sex induce cancer in the prostate?...

The Prostate Cancer Medicine market dynamics, forces, companies and trends have been determined after conducting a detailed study of the industry for this newly released research report now available with Market Study Report. A comprehensive research study on Prostate Cancer Medicine market introduced by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Prostate Cancer Medicine market in terms of the demand landscape, driving factors and growth strategies adopted by market players. Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence. Request a sample Report ...

The signs of prostate cancer can be subtle . They can range from difficulty urinating to difficulty ejaculating. A prostate-specific antigen (PSA) test can tell you whether you might have prostate cancer. Although prostate cancer is one of the most curable types of cancer out there, it is a lot easier to treat during the earlier stages. It's hard to find it in the early stages, however, if you aren't experiencing any particularly signs that it might be happening. That being said, there are subtle changes in your body that you may notice overall if you pay close attention. If you do notice any of the following early signs, Dr. Bruce Sloane, practicing urology physician in Philadelphia, said that a prostate-specific antigen (PSA) test is the only sure indicator of early stages of prostate cancer. According to the Prostate Cancer Foundation , when a problem within the prostate arises, typically more PSA is released, and higher amounts of PSA can be detected in the bloodst...

A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the U.S. Men whose prostate cancer tumors are localized typically survive many years after diagnosis, whether they have surgery, radiation therapy or no treatment at all. But for a minority of men whose cancer spreads to other parts of the body and resists hormone therapy, the prognosis is poor, with fewer than a third surviving five years after diagnosis. More than 29,000 men in the U.S. die from prostate cancer each year, according to the American Cancer Society. "We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said Michae...

If you’re a smoker looking for another reason to quit, consider this: in addition to raising your risk of heart and lung disease, as well as cancers of the bladder and kidney, smoking could boost the odds that you will develop aggressive prostate cancer that metastasizes, or spreads through your body. That’s according to research published by an Austrian team in 2018. The evidence connecting tobacco use with prostate cancer (which tends to grow relatively slowly) isn’t as strong as it is for other smoking-related diseases. Researchers first detected the link only after pooling data from 51 studies that enrolled over four million men. Published in 2014 , this earlier research showed that smokers have a 24% higher risk of death from prostate cancer than nonsmokers, but it left an open question: did the men who died from these other causes also have high-grade prostate cancers that had not yet been detected? Experts suspected that since smoking kills in different ways, some of those who...

November 26, 2018 Share this content: Patients whose radical prostatectomy was delayed more than 6 months had a nearly 2-fold increased risk of biochemical recurrence, a study found. Delaying primary treatment of prostate cancer (PCa) up to 6 months does not appear to adversely affect outcomes, but longer delays can increase the likelihood of biochemical recurrence of disease, according to a new study. “Time to receive treatment or treatment delays is an important quality metric in patient-centered care that has been shown to impact outcome among various cancers,” said study investigator Kosj Yamoah, MD, PhD, an oncologist and an Assistant Professor in the Department of Radiation Oncology and Cancer Epidemiology at H. Lee Moffitt Cancer Center in Tampa, Florida. “However, the clinical implications of delays in prostate cancer treatment remain unclear, with some studies suggesting no association between treatment delays and prostate cancer outcomes.” Continue Reading Below D...

CURRENTLY VIEWING All Specialties Select Topic: Browse by Series: [embedded content] Transcript: Transcript: View Conference Coverage Online CME Activities https://ift.tt/2P6ucXI

The development of versatile antitumor agents with tumor-imaging, targeting and therapeutic activity is promising for clinical cancer therapy. Prostate cancer is still the one of the leading threats to males. Current therapies have restricted clinical efficiency for patients with advanced and metastatic prostate cancer. Recent studies demonstrate that monoamine oxidase A (MAOA) levels elevate with prostate cancer aggression and metastasis. In addition, MAOA inhibitor therapies have been reported as an effective means to reduce the metastasis of prostate cancer and extend mouse survival. Thus, these findings provide evidence that MAOA is promising for the treatment of metastatic and advanced prostate cancer. Herein, three isoniazid (INH)-dye conjugates were synthesized by conjugating MAOA inhibitor INH with mitochondria-targeting NIRF heptamethine dyes to improve the therapeutic efficacy of prostate cancer. These INH-dye conjugates could accumulate in PC-3 cellular mitochondria via orga...

November 26, 2018 Share this content: Patients whose radical prostatectomy was delayed more than 6 months had a nearly 2-fold increased risk of biochemical recurrence, a study found. Delaying primary treatment of prostate cancer (PCa) up to 6 months does not appear to adversely affect outcomes, but longer delays can increase the likelihood of biochemical recurrence of disease, according to a new study. “Time to receive treatment or treatment delays is an important quality metric in patient-centered care that has been shown to impact outcome among various cancers,” said study investigator Kosj Yamoah, MD, PhD, an oncologist and an Assistant Professor in the Department of Radiation Oncology and Cancer Epidemiology at H. Lee Moffitt Cancer Center in Tampa, Florida. “However, the clinical implications of delays in prostate cancer treatment remain unclear, with some studies suggesting no association between treatment delays and prostate cancer outcomes.” Continue Reading Below D...

A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the U.S. Men whose prostate cancer tumors are localized typically survive many years after diagnosis, whether they have surgery, radiation therapy or no treatment at all. But for a minority of men whose cancer spreads to other parts of the body and resists hormone therapy, the prognosis is poor, with fewer than a third surviving five years after diagnosis. More than 29,000 men in the U.S. die from prostate cancer each year, according to the American Cancer Society. "We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said Michae...